<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Allergy, Asthma and Immunology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>5</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2006</Year>
        <Month>12</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">HTLV-I Infection: Virus structure, Immune Response to the Virus and Genetic Association Studies in HTLV-I-Infected Individuals</title>
    <FirstPage>153</FirstPage>
    <LastPage>166</LastPage>
    <AuthorList>
      <Author>
        <FirstName></FirstName>
        <LastName>Houshang Rafatpanah</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
      <Author>
        <FirstName></FirstName>
        <LastName>Reza Farid</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
      <Author>
        <FirstName></FirstName>
        <LastName>Gelareh Golanbar</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
      <Author>
        <FirstName></FirstName>
        <LastName>Farahzad Jabbari Azad</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>01</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Although the structure of human T lymphoptropic virus type I (HTLV-I) has been known well, the function of some proteins encoded by HTLV-I PX region is not fully understood. Furthermore, the responses of the immune system to HTLV-I remain still unknown. Most of HTLV-I-infected individuals show a strong and persistently activated cytotoxic T-cell (CTL) response to the virus. The frequency of HTLV-I specific CTL is higher in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) compared with HTLV-I carriers. However, the efficacy of the immune response determines the outcome of HTLV-I-associated diseases. Among the risk factors which contribute to the observed differences between HAM/TSP patients and HTLV-I carriers, the interaction between different genes and/or environmental factors seem to be important. These factors may also involve in outcome of HTLV-I infection in infected-individuals.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/149</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/149/149</pdf_url>
  </Article>
</Articles>
